Northwest Biotherapeutics (OTCMKTS:NWBO) Releases Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) announced its quarterly earnings data on Friday. The biotechnology company reported ($18.22) earnings per share for the quarter, Zacks reports. The company had revenue of $0.20 million during the quarter.

Northwest Biotherapeutics Stock Performance

NWBO stock opened at $0.24 on Friday. The company has a market capitalization of $369.04 million, a PE ratio of -4.00 and a beta of -0.56. Northwest Biotherapeutics has a one year low of $0.17 and a one year high of $0.48. The company’s 50 day moving average price is $0.24 and its two-hundred day moving average price is $0.26.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.